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ttenuated Coronary
ollateral Function
fter Drug-Eluting
tent Implantation
New Downside of
rug-Eluting Stents?*
orton J. Kern, MD, FACC, FSCAI, FAHA
range, California
aution has been, and should continue to be, the watch-
ord for coronary artery stent implantation. Astute cardi-
logists should not be lulled to sleep in the face of the
verwhelming everyday success of their expert interven-
ional colleagues’ skill in the use of drug-eluting stents
DES). Despite its revolutionary advances, DES implanta-
ion has a downside. In addition to the rare complications
nown to occur during the implantation procedure (exten-
ive dissection, emboli, perforation, side branch occlusion,
arly abrupt closure, and so on), DES are associated with
ate subacute thrombosis despite perfect implantation tech-
ique and concomitant antiplatelet therapy (1).
See page 15
In this issue of the Journal, Meier et al. (2) identify a new
ownside to DES: the late attenuation of collateral func-
ion. Recall that the most important, if not the only, role of
oronary collaterals is to protect the myocardium from
schemia. The rate and type of collateral recruitment with or
ithout angiogenesis vary greatly and for reasons not
ompletely understood (3). Acute recruitment of collateral
ow can be demonstrated in some normal hearts without
oronary artery disease (4). However, in most but not all
atients with chronic ischemic heart disease, collaterals are
ecruited slowly, forming gradually over time. Responding
o loss of distal coronary perfusion pressure and intermittent
schemia, angiogenic growth factors and other mediators are
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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superoxygenation system).ostulated to promote formation of new capillary pathways,
hus improving perfusion to the challenged myocardial bed
5,6). In other patients, for example, some acute myocardial
nfarction (MI) patients, collaterals are acutely recruited,
pening immediately during abrupt arterial occlusion and
erving to limit what would otherwise be extensive MI.
It is also important to note that collateral function can
hange after coronary intervention. Opening a chronic
otally occluded vessel with percutaneous angioplasty alters
he microcirculatory responses (7,8). Abrupt occlusion of a
ewly recanalized chronic total coronary artery occlusion
ay result in an MI even though substantial preexisting
ollaterals protected the myocardium before opening the
cclusion. The restored perfusion after percutaneous coro-
ary intervention (PCI) changed the collateral bed re-
ponses for the worse (9).
ollateral function after stenting. Meier et al. (2) studied
20 patients undergoing repeat PCI 6 months after bare-
etal stent (BMS, n  60) and DES (n  60) implanta-
ion, matching patients for clinical and angiographic fea-
ures including the in-stent stenosis severity. The collateral
ow index (CFI  coronary occlusion pressure/aortic pres-
ure  central venous pressure) was measured during stent
mplantation using a pressure sensor angioplasty guidewire
nd invasively determined again at a follow-up catheteriza-
ion. The functional impact of collaterals was also correlated
o ischemic tolerance, as measured by intracoronary electro-
ram ST-segment elevation (0.1 mV) during ischemia
nduced by balloon coronary occlusion.
Despite similar clinical and angiographic characteristics
ith equal in-stent stenosis severity (46  34% and 45 
6%) at follow-up (6.2 10 months and 6.5  5 months),
FI was reduced in the DES group compared with the
MS group (0.154 0.097 vs. 0.224 0.142; p 0.0049).
oreover, CFI failed to prevent ischemia (by intracoronary
CG), which occurred more frequently in the DES group
50 of 60) than in the BMS group (33 of 60, p  0.001).
his effect was less pronounced in sirolimus-DES than
aclitaxel-DES.
This study points to a new downside of DES (applicable
o both sirolimus and paclitaxel): late impairment of collat-
ral function might contribute to an increased ischemic
urden in the event of late subacute thrombosis, and this
oss could lead to more serious cardiac events when abrupt
oronary occlusion occurs.
hy would the drugs on DES have an influence on
ollateral function? Sirolimus (rapamycin) and tacrolimus
paclitaxil) are potent immunosuppressant and antiprolif-
rative drugs. Tacrolimus reduces peptidyl-prolyl
somerase activity by binding to the immunophilin
KBP-12 (FK506-binding protein), creating a new com-
lex (FKBP12-FK506) that interacts with and inhibits
alcineurin, thus inhibiting both T-lymphocyte signal trans-
uction and interleukin (IL)-2 transcription and produc-
ion. In a similar, but not identical, way, sirolimus acts by
b
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Editorial Comment January 2/9, 2007:21–2inding to the cytosolic protein FK-binding protein 12
FKBP12), However, the sirolimus-FKBP12 complex does
ot affect calcineurin but rather inhibits the mammalian
arget of rapamycin (mTOR) pathway through derepression
f PP2A, inhibiting lymphocyte proliferation and responses
o IL-2 as well as blocking the activation of T- and B-cells.
ome of these mechanisms likely affect either the stimuli of
r direct response to collateral angiogenesis (6,10).
timuli to collateral development. Few pathogenetic fac-
ors have been described that favorably or unfavorably
nfluence collateral development and angiogenesis. The
uration of myocardial ischemic symptoms and the severity
f epicardial stenotic lesions (physiologically speaking) are
he best known stimuli to collateralization (5,11). In Meier
t al. (2), no evident difference in clinical presentations
mong patient groups was seen. Angiogenesis often accom-
anies tumor growth and development. Rapamycin inhibits
etastatic tumor growth in in vivo mouse models (12).
oes the inhibition of the associated carcinogenic angio-
enic mechanisms play a role in collateral growth impair-
ent? The answer is not known. However, the anti-
ngiogenic properties of rapamycin are linked to decreased
roduction of vascular endothelial growth factor (VEGF)
nd an inhibited response of vascular endothelial cells to
timulation by VEGF. Peripheral blood mononuclear cells
rom healthy human volunteers were inhibited by sirolimus
o outgrow to smooth muscle-like and endothelial cell-like
ells (early neointimal hyperplasia) (13). Thus, although
irolimus acts against large-vessel restenosis, it is conceiv-
ble that its inhibitory effect on smooth-muscle progenitor
ells affects re-endothelialization or distant angiogenesis.
nterestingly, the adverse effects of DES on endothelializa-
ion and endothelial function have been shown only for
irolimus-eluting stents, but collateral function attenuation
as seen for both sirolimus and paclitaxel in the study by
eier et al. (2). The important new findings that both
irolimus and paclitaxel elicit a negative effect on collateral
unction, and that the effect of sirolimus appears to be less
ronounced than that of paclitaxel, require further explora-
ion into mechanisms of collateral stimulation angiogenesis
eyond our current understanding.
tudy limitations. The limitations of the current study are
ew. The investigators have a long and distinguished track
ecord of successful explorations in the subtleties of directly
easured coronary physiologic responses in patients during
ardiac catheterization. The technical feat of such data
ollection, coupled with ischemic quantification, should be
cknowledged, and its limitations would be unlikely to yield
purious results. The need to study collateral function over
ime from the large data bank of BMS- and DES-treated
atients did not permit randomization beforehand and
imited intra- and intergroup comparisons. It is understand-
ble why the limited applications of BMS precluded such
tudy. Finally, concerns may exist regarding individual
ropensities to form collaterals that might skew the results.
o clinical study can guarantee precise patient matching,ut the statistical analysis appeared to discount this factor as
n important influence on the results.
linical implications. This study highlights a previously
nappreciated downside of DES. Although it is still of
argely theoretical concern, should abrupt late occlusion
ccur after DES, the normal collateral protection would be
mpaired to some degree, with more ischemia potentially
ermitting a larger ischemic insult and higher mortality risk
han would otherwise occur. No one would question the
cceptance of this downside given the superior long-term
estenosis results for the vast majority of our patients with
ES. The observations from this study serve to focus our
ttention on how and why collaterals act to protect the heart
nd what the future might hold for pharmacologic manip-
lation of collateral function.
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